Department of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Immunology. 2010 Jul;130(3):329-36. doi: 10.1111/j.1365-2567.2010.03283.x. Epub 2010 May 10.
Interleukin-1beta (IL-1beta) is a potent inflammatory cytokine, which is implicated in acute and chronic inflammatory disorders. The activity of IL-1beta is regulated by the proteolytic cleavage of its inactive precursor resulting in the mature, bioactive form of the cytokine. Cleavage of the IL-1beta precursor is performed by the cysteine protease caspase-1, which is activated within protein complexes termed 'inflammasomes'. To date, four distinct inflammasomes have been described, based on different core receptors capable of initiating complex formation. Both the host and invading pathogens need to control IL-1beta production and this can be achieved by regulating inflammasome activity. However, we have, as yet, little understanding of the mechanisms of this regulation. In particular the negative feedbacks, which are critical for the host to limit collateral damage of the inflammatory response, remain largely unexplored. Recent exciting findings in this field have given us an insight into the potential of this research area in terms of opening up new therapeutic avenues for inflammatory disorders.
白细胞介素-1β(IL-1β)是一种有效的炎症细胞因子,与急性和慢性炎症性疾病有关。IL-1β 的活性受到其无活性前体蛋白的蛋白水解切割调节,从而产生细胞因子的成熟、有生物活性的形式。IL-1β 前体的切割由半胱氨酸蛋白酶 caspase-1 执行,该酶在称为“炎症小体”的蛋白质复合物内被激活。迄今为止,基于能够引发复合物形成的不同核心受体,已经描述了四种不同的炎症小体。宿主和入侵病原体都需要控制 IL-1β 的产生,这可以通过调节炎症小体的活性来实现。然而,我们对这种调节的机制知之甚少。特别是对于宿主限制炎症反应的附带损伤的负反馈,在很大程度上仍未得到探索。该领域的最新令人兴奋的发现使我们深入了解了这一研究领域的潜力,为炎症性疾病开辟了新的治疗途径。